Literature DB >> 8358728

Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin.

C J Koch1.   

Abstract

Toxicity from drugs activated by bioreductive metabolism has been suggested as a means to eliminate the treatment resistance caused by hypoxic tumor cells. In general, drugs have been selected to maximize the hypoxic cytotoxicity ratio [exposure (drug concentration x time) in air:exposure in nitrogen] to cause equal toxicity. On this basis, two recently developed drugs have very similar characteristics; an aziridine derivative of misonidazole (RSU1069) and a benzotriazine di-N-oxide (SR4233). The oxygen dependence of the toxic response has not previously been characterized. This report shows that the toxicity from SR4233 extends over a much greater range of oxygen concentrations than does that of RSU1069. Furthermore, unlike all previous drugs studied, the toxicity of SR4233 does not level off at high oxygen concentrations, but continues to decrease as the oxygen concentration increases. For 1 mM oxygen (the solubility of oxygen in medium at 37 degrees C equilibrated with 100% oxygen and water vapor) the toxicity from SR4233 is at least 2000-fold less than that for hypoxia. Modeling the effect of oxygen on combined radiation and toxicity shows that radiation plus SR4233 should be much more effective in eliminating hypoxic cells than radiation plus RSU1069. The unusual oxygen dependence of toxicity by SR4233 may indicate a unique biochemical activation process.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8358728

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

1.  Microdialysis sampling with on-line microbore HPLC for the determination of tirapazamine and its reduced metabolites in rats.

Authors:  K J McLaughlin; A A Faibushevich; C E Lunte
Journal:  Analyst       Date:  2000-01       Impact factor: 4.616

2.  DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine.

Authors:  M J Dorie; M S Kovacs; E C Gabalski; M Adam; Q T Le; D A Bloch; H A Pinto; D J Terris; J M Brown
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

3.  Hypoxia-activated cytotoxic agent tirapazamine enhances hepatic artery ligation-induced killing of liver tumor in HBx transgenic mice.

Authors:  Wei-Hsiang Lin; Shiou-Hwei Yeh; Kun-Huei Yeh; Kai-Wei Chen; Ya-Wen Cheng; Tung-Hung Su; Ping Jao; Lin-Chun Ni; Pei-Jer Chen; Ding-Shinn Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-04       Impact factor: 11.205

4.  Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.

Authors:  Kevin O Hicks; Bronwyn G Siim; Jagdish K Jaiswal; Frederik B Pruijn; Annie M Fraser; Rita Patel; Alison Hogg; H D Sarath Liyanage; Mary Jo Dorie; J Martin Brown; William A Denny; Michael P Hay; William R Wilson
Journal:  Clin Cancer Res       Date:  2010-08-20       Impact factor: 12.531

Review 5.  Targeting hypoxia in cancer therapy.

Authors:  William R Wilson; Michael P Hay
Journal:  Nat Rev Cancer       Date:  2011-06       Impact factor: 60.716

6.  Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study.

Authors:  Paul A DiSilvestro; Shamshad Ali; Peter S Craighead; Joseph A Lucci; Yi-Chun Lee; David E Cohn; Nicola M Spirtos; Krishnasu S Tewari; Carolyn Muller; Walter H Gajewski; Margaret M Steinhoff; Bradley J Monk
Journal:  J Clin Oncol       Date:  2014-01-06       Impact factor: 44.544

Review 7.  Optimizing hypoxia detection and treatment strategies.

Authors:  Cameron J Koch; Sydney M Evans
Journal:  Semin Nucl Med       Date:  2015-03       Impact factor: 4.446

Review 8.  [Radiotherapy, chemotherapy and target therapy for treatment of head and neck cancer : new developments].

Authors:  R Knecht
Journal:  HNO       Date:  2009-05       Impact factor: 1.284

9.  Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy.

Authors:  Rob A Cairns; Ioanna Papandreou; Patrick D Sutphin; Nicholas C Denko
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-15       Impact factor: 11.205

10.  Tirapazamine plus cisplatin and irradiation in a mouse model: improved tumor control at the cost of increased toxicity.

Authors:  Markus Adam; Christine Bayer; Julia Henke; Anca Grosu; Michael Molls; Carsten Nieder
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-11       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.